Side-by-side · Research reference

5-Amino-1MQvsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BFDA-ApprovedVerified15/53 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

5-Amino-1MQ

Semaglutide

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Semaglutide

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

Once weekly, same day each week

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Duration

8–12 weeks per cycle

Indefinite for chronic indication

Discontinuation results in weight regain.

Form

Oral capsule

—

Timing

Morning fasted preferred

Any time of day, with or without food

Half-life

Hours (estimated; no human PK published)

~7 days (168 h)WEGOVY (semaglutide) injection 2021

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

Reconstitution

—

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

04Side Effects & Safety

Parameter

5-Amino-1MQ

Semaglutide

GI symptoms

Mild nausea (anecdotal)

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

ContraindicatedWEGOVY (semaglutide) injection 2021

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

5-Amino-1MQ

Semaglutide

1. Form

Oral capsule. No injection.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Administration

Take with water, fasted preferred.

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Timing

Morning fasted.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Storage

Room temp ≤25 °C, dry place.

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Caveat

Monitor B-vitamin status with chronic use.

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

5-Amino-1MQ

— no documented stacks

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)